The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

If you continue to have this issue please contact [email protected]. More than 80% of Omvoh responders from the VIVID-1 study maintained endoscopic response at week 104 in VIVID-2.

We recently compiled a list of the 12 Best Long-Term Stocks to Buy According to Ken Fisher. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the ...

Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections Inspira announced its bio-electronic ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

In the past two years, Lilly has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca. Its new drugs ...

In the past two years, Lilly has received approvals for several new drugs like Kisunla, Omvoh and Jaypirca. Its new drugs contributed significantly to its top-line growth in 2024. Lilly is also ...

UPDATED: Thursday, Jan. 16 at 10:25 a.m. ET Eli Lilly's Omvoh has picked up its second major FDA nod. After the IL-23 inhibitor's approval in 2023 to treat ulcerative colitis, the agency has now ...

INDIANAPOLIS—Lilly Endowment Inc., a major shareholder in Eli Lilly & Co. (NYSE:LLY), has recently sold a significant portion ...

and Tremfya (guselkumab), Eli Lilly's Omvoh (mirikizumab), and Sun Pharma's Ilumya (tildrakizumab). Oral IL-23-directed alternatives are starting to filter through the industry pipeline that aim ...